secwatch.observer — SEC 8-K summary
======================================

Issuer:     CapsoVision, Inc (CV)
CIK:        0001378325
Form:       8-K
Filed at:   2026-08-13T20:07:15+00:00
Accession:  0001378325-26-000035
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 1.01, 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CapsoVision Q2 revenue $3.6M (+10% YoY), gross margin 51%, ATM up to $100M
--------------------------------------------------------------------------

- Q2 revenue $3.6M, up 10% YoY; gross margin 51% vs 55% on pricing pressure and tariffs.
- Operating expenses $9.5M, up $3.0M YoY; cash $9.1M at June 30, 2026.
- Entered ATM equity offering up to $100M with Cantor Fitzgerald; 3% commission.
- Launched AI Highlights™ internationally; FDA clearance expected by end of Q3 2026.
- Appointed David S. Shields, M.D. to Board effective July 1, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1378325/000137832526000035/0001378325-26-000035-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1378325/000137832526000035/cv-20260813.htm
  HTML page:      https://secwatch.observer/filing/0001378325-26-000035

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer